Wiz, I assume you mean HGSI, Human Genome. Yes, I follow both. I held a full position in HGSI when it was in the teens and then traded it several times from the high teens and low 20s to the high 30s. I haven't been in it in a while. I love the co., but it was the first genome stock to get way overpriced and I moved on to Incyte and Gene until they got way overpriced. Incyte and Gene are actually nearing buy points again, but Human Genome still looks bloated to me.
I have admired Celera from afar, but it has not been cheap enough for me lately. It almost hit a buy point last week, but then, it bounced.
Effectively, Celera looks to dominate the low end of the gene sequencing racket, while HGSI, INCY and GENE fight over the more complex constructions. I think there is plenty of room for all, but the big question mark is not resolved no matter how high the stocks go in price. Can you really patent a human gene? If not, Houston, we've got a problem. This won't really be a legal problem until we get some drugs based upon the mapping, but I'm not convinced that the companies can claim any sort of exclusivity. I am much more convinced when Gene is at $5 and Incy is at $17. <g> Or, more willing to give them the benefit of the doubt when doubt dominates the stock prices. |
